Perceptions of chemoprevention among individuals at high risk of oral cancer: qualitative study within the UK-based SAVER trial

PMCID: PMC12182162

PMID: 40527552

DOI: 10.1136/bmjopen-2025-101326

Journal: BMJ open

Publication Date: 2025

Authors: Sherratt F, McCarthy C, Jiménez-Tomàs A, Perry J, Kuruvilla R, et al.

Key Points

• Individuals with oral epithelial dysplasia are generally open to chemoprevention research, motivated by potential cancer risk reduction
• Most participants (11/20) were randomized in the trial, demonstrating willingness to engage in preventive research
• Effective patient communication and addressing individual concerns are crucial for successful clinical trial recruitment in cancer prevention studies

Summary

This qualitative study explored patient perspectives on a novel chemoprevention trial (SAVER) targeting oral epithelial dysplasia (OED), a precursor to oral squamous cell carcinoma. Researchers conducted semi-structured interviews with 20 individuals to understand their attitudes toward participating in a clinical trial investigating sodium valproate's potential to prevent malignant transformation.

The study revealed that most participants were receptive to chemoprevention, particularly those with extensive histories of oral health interventions. However, participants expressed significant concerns about medication side effects, biopsy procedures, and potential treatment delays. Critically, the research highlighted the importance of empathetic communication, clear trial explanations, and comprehensive patient support in facilitating clinical trial recruitment and participation.